Results for Incretin

Publications & Outputs

1. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model

   Zhang, L., Zhang, L., Li, L. & Hölscher, C., 10/2018, In: Neuropeptides. 71, p. 70-80 11 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

2. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model

   Shi, L., Zhang, Z. & Hölscher, C., 1/06/2017, In: Behavioural Brain Research. 327, p. 65-74 10 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

3. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

   Jalewa, J., Sharma, M. K., Gengler, S. & Hölscher, C., 1/05/2017, In: Neuropharmacology. 117, p. 238-248 11 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

4. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF

   Ji, C., Xue, G-F., Lijun, C., Feng, P., Li, D., Li, L., Li, G. & Holscher, C., 1/03/2016, In: Brain Research. 1634, p. 1-11 11 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

5. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model

   Zhang, Y., Chen, Y., Li, L. & Holscher, C., 15/10/2015, In: Behavioural Brain Research. 293, p. 107-113 7 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review

6. Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease

   Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L. & Hölscher, C., 2015, In: European Journal of Pharmacology. 765, p. 284-290 7 p.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review